Clinical Oncology
Volume 21, Issue 7 , Pages 536-542, September 2009

Radiochemotherapy for Lung Cancer in Developing Countries

  • L. Kepka

      Affiliations

    • Department of Radiation Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Corresponding Author InformationAuthor for correspondence: L. Kepka, Department of Radiation Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, ul. Roentgena 5, 02-781 Warsaw, Poland.Tel: +48-22-506118-893; Fax: +48-22-641-87-28.
  • ,
  • F. Casas

      Affiliations

    • Radiation Oncology Department, University Clinic, Barcelona, Spain
  • ,
  • B. Perin

      Affiliations

    • Institute for Lung Diseases, Sremska Kamenica, Serbia
  • ,
  • S. Abdel-Wahab

      Affiliations

    • Department of Radiation Oncology, Ain Shams University, Cairo, Egypt
  • ,
  • T. Saghatelyan

      Affiliations

    • Department of Radiation Oncology, National Cancer Institute, Yerevan, Armenia
  • ,
  • L. Vashkevitch

      Affiliations

    • Department of Radiation Oncology, N. Alexandrov Research Institute of Oncology, Minsk, Belarus
  • ,
  • P.M. Gaye

      Affiliations

    • Institut Dantec, Dakar, Senegal
  • ,
  • D. Dawotola

      Affiliations

    • Department of Radiation Oncology, Zaria, Nigeria
  • ,
  • J.P. Agarwal

      Affiliations

    • Tata Memorial Centre, Mumbai, India
  • ,
  • B. Jeremic

      Affiliations

    • International Atomic Energy Agency, Vienna, Austria

Received 13 March 2009; accepted 1 April 2009.

Abstract 

Radiochemotherapy has become a standard approach in locally advanced non-small cell lung cancer and limited disease small cell lung cancer. Most of the data supporting this observation come from the developed world and only extremely rarely have good-quality clinical trials been carried out in developing countries. It is therefore of paramount importance to put the experience of the developed world into the context of the limited resources and other health care problems of developing countries. In this overview, the problems with the implementation of such data are discussed. The necessity of carrying out clinical trials specifically designed to address the needs of developing countries is emphasised. The research on cheaper ways of radiochemotherapy combination should be encouraged. The specific national guidelines for local needs should be created and followed. The availability of radiotherapy equipment is of major importance, as radiotherapy has a pivotal role in non-surgical treatment of lung cancer, especially in the developing world.

Key words: Chemotherapy, combined treatment, developing countries, elderly, lung cancer, radiotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(09)00111-3

doi:10.1016/j.clon.2009.04.001

Clinical Oncology
Volume 21, Issue 7 , Pages 536-542, September 2009